MedWatch

Action Pharma-founder to build new biotech company out of the rubble

Founder of the biotech company Action Pharma have bought the remains of the research from the recently dispersed company, and is now teaming up with colleagues in an effort to create another biotech success.

Søren Nielsen founded Action Pharma at the turn of the millennium, and the research – which he was responsible for as CSO in the company – has now been bought by the American pharmaceutical giant Abbott. The biotech company’s greatest asset, the candidate drug AP214 against kidney failure, is now in the hands of Abbott.

But the adventure isn’t over for Søren Nielsen, who is currently working as a professor at Aarhus University. He has bought the remaining research that Action Pharma conducted in addition to the work on AP214.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier